secwatch.observer — SEC 8-K summary
======================================

Issuer:     TELA Bio, Inc. (TELA)
CIK:        0001561921
Form:       8-K
Filed at:   2022-05-10T23:59:59+00:00
Accession:  0001104659-22-058223
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TELA Bio Q1 revenue $8.2M (+40% YoY); net loss widens to $10.9M
---------------------------------------------------------------

- Revenue grew 40% YoY to $8.2M; OviTex PRS revenue up 111% YoY.
- Gross margin improved to 61% from 59% on lower excess/obsolete inventory adjustments.
- Net loss $10.9M vs $8.1M; operating loss $9.8M vs $7.3M.
- Cash and equivalents $33.0M; FY2022 revenue guidance reaffirmed at $40-45M.
- Appointed D. Taylor Ocasio as General Counsel.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922058223/0001104659-22-058223-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1561921/000110465922058223/tm2215020d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-058223

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer